Pediatric Oncology

CHICAGO — In what researchers described as the first randomized controlled trial of chemotherapy in relapsed or refractory Ewing sarcoma, high-dose ifosfamide proved more effective in extending survival than topotecan and cyclophosphamide.

CHICAGO — The keynote speaker at ASCO Annual Meeting urged attendees to focus on social and organizational innovations that can advance equity in cancer care.

Hispanic children with high-risk neuroblastoma had worse survival outcomes than other children with the disease despite receiving treatment on clinical trials with standardized protocols, according to study results.

The FDA approved azacitidine for treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.

Kathleen Shannon Dorcy, PhD, RN, FAAN, received this year’s Connie Henke Yarbro Excellence in Cancer Nursing Mentorship Award.

Survivors of adolescent and young-adult acute myeloid leukemia and acute lymphoblastic leukemia had lower long-term survival rates than the general population, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.

Younger patients who developed treatment-related hemophagocytic lymphohistiocytosis after tisagenlecleucel infusion for relapsed or refractory B-cell acute lymphoblastic leukemia had significantly poorer outcomes, according to study results.

Fludarabine exposure appeared associated with improved clinical outcomes among pediatric patients undergoing chimeric antigen receptor T-cell therapy for refractory or relapsed B-cell acute lymphoblastic leukemia, study results showed.

SALT LAKE CITY — Early azithromycin use did not affect hematologic relapse among pediatric hematopoietic stem cell transplant recipients, according to study results.

SALT LAKE CITY — Pediatric and young adult survivors of acute leukemia who underwent allogeneic hematopoietic stem cell transplantation appeared to be at increased risk for late mortality, according to study results.